# GC101 TIL

Source: https://onco.cc/drugs/gc101-til/  
OnCo record `gc101-til` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GC101 TIL is an experimental tumour-infiltrating lymphocyte therapy from Shanghai Juncell Therapeutics in phase 2 trials for melanoma, aimed at PD-1 and BRAF.

## Summary

GC101 TIL (GC101) is a tumour-infiltrating lymphocyte therapy developed by Shanghai Juncell Therapeutics. Its targets are PD-1, BRAF and MEK1/2 (the sponsor names melanoma and non-small cell lung cancer (solid tumours)). The sponsor states: An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration. ClinicalTrials.gov describes the intervention as: Patients with advanced melanoma (excluding uveal melanoma) who have failed to PD-1 antibodies (if BRAF mutation is present, BRAF and MEK inhibitors have failed; if NRAS mutation is present, tunlametinib have failed) and are ineligible for r. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in melanoma. The largest, NCT06703398, plans to enrol 98 participants with primary completion was scheduled for 2026-05-12 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: GC101
- Modality: TIL therapy
- Mechanism: An autologous natural TIL cell therapy administered without high-intensity lymphodepleting chemotherapy and without IL-2 administration.

## Sources

- ClinicalTrials.gov: trials of GC101 TIL: https://clinicaltrials.gov/search?intr=GC101
- Sponsor page: https://www.juncell.com/

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [BRAF](https://onco.cc/targets/braf/), [MEK1/2](https://onco.cc/targets/mek/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Shanghai Juncell Therapeutics](https://onco.cc/companies/shanghai-juncell-therapeutics/)
- trials: [A Phase II Study of GC101 in NSCLC](https://onco.cc/trials/nct07560111/), [A Study of GC101 TIL in Advanced Melanoma](https://onco.cc/trials/nct06703398/)

---
JSON: https://onco.cc/api/v1/entities/gc101-til.json